Thank you for your continued loyalty to the

• Sanofi Influenza Vaccine Portfolio •

It is our ongoing commitment to simplify your vaccine choices for your eligible patients.

2024-2025 Season

	Packaging	Ages[1-3]	Presentation[1-3]	Dosing Schedule[1-4]	CPT®[a] Codes & Coverage[5]	NDC[b] Information[6] Package NDC	NDC[b] Information[6] Unit NDC	EMR[c] Code
Fluzone® High-Dose Influenza Vaccine		**65 years** of age and older	**0.5-mL** single-dose prefilled syringe	**1 dose**	**90662** Covered by most health plans and Medicare Part B	49281-0124-65	49281-0123-88	
Flublok® Influenza Vaccine		**18 years** of age and older	**0.5-mL** single-dose prefilled syringe	**1 dose**	**90673** Covered by most health plans and Medicare Part B	49281-0724-10	49281-0723-88	
Fluzone® Influenza Vaccine		**6 months** of age and older	**0.5-mL** single-dose prefilled syringe	**1 or 2 doses** Please refer to the Prescribing Information for further information on dosing schedule.	**90656** Covered by most health plans and Medicare Part B	49281-0424-50	49281-0423-88	
			**5-mL** multi-dose vial Maximum of 10 doses can be withdrawn		**90657** *(0.25-mL dose)* **90658** *(0.5-mL dose)* Covered by most health plans and Medicare Part B	49281-0641-15	49281-0639-78	

[a]CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association. [b]NDC=National Drug Code. [c]EMR=electronic medical record. [d]ACIP=Advisory Committee on Immunization Practices.

Notice: This coding guide is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician's independent diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change. Providers are solely responsible for the accuracy of all coding and claims submitted for reimbursement to any third-party payer.

Indications:

Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. Fluzone is approved for use in persons 6 months of age and older. Flublok is approved for use in persons 18 years of age and older. Fluzone High-Dose is approved for use in persons 65 years of age and older.

IMPORTANT SAFETY INFORMATION FOR FLUZONE® (INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND FLUZONE® HIGH-DOSE (INFLUENZA VACCINE)

Do not administer Fluzone, Flublok, or Fluzone High-Dose to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone and Fluzone High-Dose). Fluzone and Fluzone High-Dose should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone, Flublok, or Fluzone High-Dose should be based on careful consideration of the potential benefits and risks.

If Fluzone, Flublok, or Fluzone High-Dose are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be attained.

Vaccination with Fluzone, Flublok, or Fluzone High-Dose may not protect all recipients.

Syncope (fainting) has been reported following vaccination with Fluzone, Flublok and Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.

For Fluzone, in children 6 months through 8 years of age, the most common injection-site adverse reactions were pain or tenderness and redness; the most common solicited systemic adverse reactions were irritability, drowsiness (6 months through 35 months), and myalgia (3 years through 8 years). In adults 18 through 64 years of age, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were headache and myalgia. In adults over 65 years of age, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were headache, myalgia, and malaise.

For Flublok, in adults 18 through 64 years of age, the most common injection site adverse reaction was pain; the most common solicited systemic adverse reactions were headache, fatigue, and myalgia. In adults 65 years of age and older, the most common injection-site adverse reaction was pain; the most common solicited systemic adverse reactions were fatigue and headache.

For Fluzone High-Dose, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, malaise, and headache.

For Fluzone, Flublok, and Fluzone High-Dose, other adverse reactions may occur.

Please click to access or refer to the accompanying Prescribing Information for Fluzone, Flublok, or Fluzone High-Dose.

References: 1. Fluzone High-Dose. Prescribing Information. Sanofi Pasteur Inc. **2.** Flublok. Prescribing Information. Protein Sciences Corporation. **3.** Fluzone. Prescribing Information. Sanofi Pasteur Inc. **4.** Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 influenza season. *MMWR Recomm Rep*. 2022;71(1):1-28. **5.** Seasonal Influenza Vaccines Pricing. Centers for Medicare & Medicaid Services. January 04, 2023. Accessed May 8, 2023. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing **6.** Data on file. Sanofi Inc. 2023.

sanofi
Sanofi.
Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofi.us MAT-US-2019281-v6.0-07/2024